SCHEMBL4903298

SCHEMBL4903298

Cc1ccc(C(=O)Nc2ccc(Nc3nccc(-c4ccccn4)n3)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 3/20 0.59
PDGFRB P09619 3/20 0.59
BCR P11274 3/20 0.59
PDGFRA P16234 3/20 0.59
JAK2 O60674 2/20 0.56
ADORA3 P0DMS8 2/20 0.56
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
MAPT P10636 1/20 0.53
EGFR P00533 1/20 0.53
PRKCA P17252 1/20 0.53
CYP3A4 P08684 2/20 0.53
SYK P43405 2/20 0.53
AURKA O14965 1/20 0.53
AURKB Q96GD4 1/20 0.53
JAK3 P52333 1/20 0.52
CAMK2D Q13557 1/20 0.52
TRPV1 Q8NER1 1/20 0.52
CYP1A2 P05177 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899247 0.90 ABL1 (0.73) ABL1PDGFRBBCRPDGFRAJAK2
SCHEMBL4899326 0.89 PDGFRB (0.56) ABL1PDGFRBBCRPDGFRAJAK2
SCHEMBL4903437 0.87 PDGFRA (0.73) ABL1PDGFRBBCRPDGFRAEGFR
SCHEMBL4899630 0.85 ABL1 (0.64) ABL1PDGFRBBCRPDGFRAJAK2
SCHEMBL4903136 0.83 PDGFRA (0.82) ABL1PDGFRBBCRPDGFRAEGFR
SCHEMBL7461995 0.83 JAK2 (0.73) JAK2SYKAURKAJAK3
SCHEMBL4897416 0.83 TRPV1 (0.53) ABL1SMN1; SMN2TRPV1
SCHEMBL4901565 0.83 MEN1 (0.59) JAK2ADORA3PRKCACYP3A4SYK
SCHEMBL3123402 0.81 ABL1 (0.74) ABL1PDGFRBBCRPDGFRAJAK2
SCHEMBL4892485 0.81 PRKCA (0.62) ABL1PDGFRBBCRPDGFRAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP ABL1 2843/4885PDGFRB 299/4885BCR 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.